Evaxion Biotech AS (EVAX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.27 (+1.55%), Market cap $0.03B, 52-week low–high $1.71 ~ $11.01.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to targe
Financial statements, price targets, institutional (13F) holdings and related news for Evaxion Biotech AS are updated in real time on BlackAll Trade.
Evaxion Biotech AS trades at $3.27 (+1.55%). Real-time quotes and charts are available on BlackAll Trade.
Evaxion Biotech AS has a market cap of about $0.03B.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the